Image de couverture de livre

GCMS and LCMS data of exometabolome of parental and Osimertinib-resistant EGFR-mutant NSCLC

Fuente: Zenodo

Enregistré dans:

Détails bibliographiques
Auteur principal:	Bramanti, Emilia
Format:	Recurso digital
Publié:	Zenodo 2025
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Possible new mechanisms of primary drug resistance in NSCLC with EGFR mutation treated with Osimertinib
par: Lujing Shao, et autres
Publié: (2025)

Sacituzumab tirumotecan improved survival for patients with EGFR TKI–resistant, EGFR‐mutant advanced NSCLC
par: Leah Lawrence
Publié: (2026)

More treatment options emerge for EGFR ‐mutant NSCLC
par: Leah Lawrence
Publié: (2026)

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
par: Xin Liao, et autres
Publié: (2024)

Reply to “High Pharmacokinetic Variability and Unrecognized Limitations in First‐Line Osimertinib Plus Chemotherapy for EGFR ‐Mutated NSCLC ”
par: Azar Shahraz, et autres
Publié: (2025)

Improved progression‐free survival, increased toxicities seen with amivantamab for EGFR‐mutant NSCLC
par: Mary Beth Nierengarten
Publié: (2024)

Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC
par: Jincheng Yang, et autres
Publié: (2025)

Persist or resist: Immune checkpoint inhibitors in EGFR‐mutated NSCLC
par: Pengcheng Zhu, et autres
Publié: (2024)

Thoracic radiotherapy synergizes with first‐line EGFR ‐ TKIs in advanced EGFR ‐mutant NSCLC : A dual‐center real‐world study
par: Zhuoying Tian, et autres
Publié: (2025)

The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis
par: Liuxian Guo, et autres
Publié: (2024)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
par: Shang‐Gin Wu, et autres
Publié: (2024)

Magnoliae flos Overcomes EGFR ‐ TKI Resistance in NSCLC by Enhancing EGFR Ubiquitination
par: Qing Wu, et autres
Publié: (2026)

Lomitapide: Targeting METTL3 to Overcome Osimertinib Resistance in NSCLC Through Autophagy Activation
par: Xiaohui Du, et autres
Publié: (2025)

Multieffect Specific Nanovesicles for Homing Resistant Tumors and Overcoming Osimertinib‐Acquired Resistance in NSCLC
par: Yuanyao Dou, et autres
Publié: (2025)

Successful Treatment of Osimertinib Resistance in an EGFR‐Mutant Lung Cancer Patient With a Rare STRN3‐ALK Fusion Using Brigatinib and Osimertinib
par: Chia‐Yu Kuo, et autres
Publié: (2025)

Deciphering the Role of Acetate in Metabolic Adaptation and Osimertinib Resistance in Non-Small Cell Lung Cancer
par: Maroni, Giorgia, et autres
Publié: (2025)

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
par: Jin Tian, et autres
Publié: (2024)

USP28 Promotes Osimertinib Resistance in H1975 NSCLC Cells by Deubiquitinating and Stabilizing SIRT1
par: Hu‐Sen Fan, et autres
Publié: (2025)

First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
par: Yugo Matsumura, et autres
Publié: (2025)

Osimertinib Cost Minimization in Non‐Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination with Cobicistat
par: Niels Westra, et autres
Publié: (2025)

Oral TKI sevabertinib approved for advanced HER2 ‐mutant NSCLC
par: Leah Lawrence
Publié: (2026)

Clinical Outcomes of Later‐Generation EGFR ‐ TKIs for Uncommon EGFR Mutations in NSCLC : A Multicenter Real‐World Study
par: Lisa Shigematsu, et autres
Publié: (2025)

Itraconazole Reversing Acquired Resistance to Osimertinib in NSCLC by Inhibiting the SHH/DUSP13B/p‐STAT3 Axis
par: Hongmei Zheng, et autres
Publié: (2024)

EGFR exon 20–targeting sunvozertinib granted accelerated approval for advanced NSCLC
par: Leah Lawrence
Publié: (2025)

Baseline and changes in inflammatory parameters for patients with EGFR‐mutated NSCLC treated with afatinib
par: Zi‐Ting Chang, et autres
Publié: (2025)

Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR ‐Mutant NSCLC
par: Yuxiang Sun, et autres
Publié: (2026)

Oral TKI zongertinib gains accelerated approval for HER2 ‐mutant NSCLC
par: Leah Lawrence
Publié: (2025)

Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes
par: Yutaro Nagano, et autres
Publié: (2026)

Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations
par: Yuko Iida, et autres
Publié: (2026)

Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy
par: Wei‐Chun Chen, et autres
Publié: (2024)

Spatial Heterogeneity of PD‐L1 Expression as a Biomarker for Third‐Generation EGFR‐TKI Response in Advanced EGFR‐Mutant NSCLC
par: Yidan Zhang, et autres
Publié: (2025)

LCMS: An R package for automated semitargeted analysis in lipidomics
par: Caroline Peltier, et autres
Publié: (2024)

The exometabolome of microbial communities inhabiting bare ice surfaces on the southern Greenland Ice Sheet
par: Eva L. Doting, et autres
Publié: (2024)

Rapid exometabolome footprinting combined with multivariate statistics: A powerful tool for bioprocess optimization
par: Alexander Reiter, et autres
Publié: (2024)

A systematic derivatization technique for characterization of ethoxylates by GC and GCMS
par: Asraf A. Ali, et autres
Publié: (2024)

Xenium and IMC data in "Spatial Single-Cell Profiling Identifies Immune-Cold Tumor Niches Linked to Early Progression on EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant NSCLC"
par: Li, Haochen, et autres
Publié: (2026)

Chapter Vivere in una società longeva: quali sfide per le generazioni
par: Donatella, Bramanti
Publié: (2026)

Chapter Per una cultura della cittadinanza attiva
par: Donatella, Bramanti
Publié: (2026)

Long‐term survival of a patient with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) and untreated multiple brain metastases treated with zorifertinib: A case report
par: Kang Li, et autres
Publié: (2024)

Repurposing bosentan as an anticancer agent: EGFR/ERK/c‐Jun modulation inhibits NSCLC tumor growth
par: Marwa M. Khalaf, et autres
Publié: (2025)